EGFRvIII peptide PEPvIII |
| Katalog-Nr.GC35967 |
Das EGFRvIII-Peptid PEPvIII ist eine tumorspezifische Mutation, die in Glioblastoma multiforme (GBM) und anderen Neoplasmen weit verbreitet ist und deren Expression die Tumorigenität verstärkt. Das EGFRvIII-Peptid stellt ein wirklich tumorspezifisches Ziel für die Antitumor-Immuntherapie dar.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 129112-17-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
EGFRvIII peptide (PEPvIII) is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide represents a truly tumor-specific target for antitumor immunotherapy[1].
[1]. Schmittling RJ, et al. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods. 2008 Nov 30;339(1):74-81.
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *